Insulet to Present at Nasdaq’s 45th Investor Conference
11/24/2021 - 06:00 AM
ACTON, Mass. --(BUSINESS WIRE)--
Insulet Corporation (NASDAQ: PODD) (Insulet ), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the virtual 45th Nasdaq Investor Conference on Friday, December 3, 2021 at 11:30 a.m. (Eastern Time) .
To listen to the live webcast of the presentation, please visit investors.insulet.com/events . A replay of the webcast will also be available following the event.
About Insulet Corporation :
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts , is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: insulet.com and omnipod.com .
View source version on businesswire.com : https://www.businesswire.com/news/home/20211124005071/en/
Investor Relations:
Deborah R. Gordon
dgordon@insulet.com
Merrill Robichaud
mrobichaud@insulet.com
Media:
Angela Geryak Wiczek
awiczek@insulet.com
Source: Insulet Corporation
PODD Rankings
#4625 Ranked by Stock Gains
PODD Stock Data
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
Tags
Health Technology, Medical Specialties, Manufacturing, Surgical and Medical Instrument Manufacturing
Country
US
City
Acton
About PODD
insulet corporation is an innovative medical device company based in billerica, massachusetts. it was founded in 2000 with the mission of improving the lives of people with diabetes. specifically, through its revolutionary omnipod insulin management system, insulet seeks to expand the use of insulin pump therapy. studies have demonstrated the advantages of insulin pump therapy over multiple daily insulin injections (mdi); these advantages include better glycemic control, fewer hypoglycemic events, reduced glycemic variability1 and improved quality of life2. despite these benefits, most people still choose mdi therapy largely due to the complexity, cost and inconvenience of conventional pump technology. the omnipod is a discreet and easy-to-use system that eliminates many of the issues associated with conventional pumps. improvements include omnipod's lack of tubing; automated, virtually pain-free insertion; and two straightforward parts that communicate wirelessly. by breaking down
